| News Release in Year 2007 | ||||||
California Clean Tech Open 15th November 2007
Mr Michael Wu, Managing Director of 3V SourceOne Capital based in the US, served as a judge for the Finals of this unique competition. Participating teams focussed solely on clean technology and were prepared to take their innovations to the marketplace.
|
||||||
Investment in Kidscape Singapore Pte Ltd 22th October 2007
3VS1 Asia Growth Fund Ltd invested in Kidscape Singapore Pte Ltd together with institution co-investors including OCBC Bank, Phillips Capital, Hotung and NIS Group.
|
||||||
Viacell Inc. acquired by PerkinElmer, Inc. October 2007 ViaCell, Inc. has been successfully acquired by PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences.
|
||||||
The Global Security Challenge 12th September 2007
Mr Tan Kim Seng, Managing Director of 3V SourceOne Capital served as a judge for this annual competition organized by London Business School and NUS Enterprise.
|
||||||
Divestment of Sino Techfibre Limited 27th April 2007
3VS1 Asia Growth Fund Ltd divested all shareholdings in Sino Techfibre Limited.
|
||||||
Asian Private Equity Partners Forum 18th April 2007
Mr Tan Kim Seng, Managing Director of 3V SourceOne Capital, was the moderator for the panel on “Valuation Guidelines: Convergence to a global standard” at the 2007 Asian Private Equity Partners Forum. This is the second time that Private Equity International hosted their annual Asian Private Equity Partners Forum at the Four Seasons Hotel Hong Kong. Key themes addressed included fundraising, LP/GP relationship, risk management, portfolio valuation and more.
The Panelists include Mr Mark Thompson, Chief Investment Officer of HSBC Private Equity Asia, Ms Monica Tsui, Managing Director of PAMA Group, Mr Avinsah Vashistha, CEO & Global Managing Partner of Tholons Inc.
|
||||||
Private Equity IQ Asia 2007 29th March 2007
Mr Tan Kim Seng, Managing Director of 3V SourceOne Capital shared his views on “The Best Private Equity Opportunities in Asia for 2007” in a panel discussion. Kim Seng and Michael further conducted a Post Conference Masterclass on the topic “Engineering Cross Border Deals”.
The key points of the Masterclass are:
|
||||||
Omeros Corporation Receives Funding 9th January 2007
Omeros Corporation announced that the Stanley Medical Research Institute (SMRI) will provide up to $9 million in equity and grant funding toward the development of Omeros’ proprietary drug candidate for the treatment of schizophrenia.
|

